StockUS listing USBCDANASDAQHealthcareEarnings Deterioration

Biocardia Inc(BCDA) Stock Analysis | Healthcare

USD --+0.00%
Reward34Low
Risk46Moderate
75%Data
Revenue down 100% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 11.88M
Reward Ratingⓘ34 Low reward assessment · 75% data coverage
Bottom 5% of stocksView factors
Risk Ratingⓘ46 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on BCDA to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Biocardia Inc?

, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.

AI Brief Pro

The brief on Biocardia Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Biocardia Inc?

, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 11.88M.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (34)
Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.654
Insider Activity
12M windowBullish
Shares soldShares bought
0-3months
0
54,200 shares
$4k
3-6months
0
15146,500 shares
$137k
6-9months
0
0
9-12months
0
0